- SARS-CoV-2 seroprevalence among healthcare workers in general hospitals and 1
- 2 clinics in Japan

5

11

- Running title: Seroprevalence of SARS-CoV-2 antibodies 4
- Tatsuya Yoshihara, MD, PhD¹; Kazuya Ito, PhD^{2,3}; Masayoshi Zaitsu, MD, PhD⁴; 6
- Eunhee Chung, PhD⁵; Izumi Aoyagi, MD⁶; Yoshikazu Kaji, MD⁷; Tomomi Tsuru, MD⁸; 7
- Takuma Yonemura, MD⁹; Koji Yamaguchi, MD¹⁰; Shinichi Nakayama, MD, PhD¹¹; 8
- Yosuke Tanaka, MD, PhD¹²; Nobuo Yurino, MD, PhD¹³; Hideki Koyanagi, MD, PhD¹⁴; 9
- Shunji Matsuki, MD, PhD¹; Ryuji Urae, MD¹⁵; and Shin Irie, MD¹⁵ 10
- ¹SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center, 3-5-1 Kashiiteriha, 12
- 13 Higashi-ku, Fukuoka 813-0017, Japan
- 14 ²SOUSEIKAI Clinical Epidemiological Research Center, 3-5-1 Kashiiteriha, Higashi-
- ku, Fukuoka 813-0017, Japan 15
- ³College of Healthcare Management, Takayanagi 960-4, Setaka-machi, Miyama 835-16
- 0018, Japan 17
- ⁴Department of Public Health, Dokkyo Medical University School of Medicine, 880 18
- 19 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan
- ⁵SOUSEIKAI Global Clinical Research Center, Kashiiteriha 3-5-1, Higashi-ku, 20
- Fukuoka 813-0017, Japan 21
- ⁶SOUSEIKAI Fukuoka Mirai Hospital, Kashiiteriha 3-5-1, Higashi-ku, Fukuoka 813-22
- 0017, Japan 23
- ⁷SOUSEIKAI Hakata Clinic, 6-18 Tenyamachi, Hakata-ku, Fukuoka 812-0025, Japan 24 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ⁸SOUSEIKAI PS Clinic, 6-18 Tenyamachi, Hakata-ku, Fukuoka 812-0025, Japan 25
- ⁹SOUSEIKAI Sumida Hospital, 1-29-1, Honjo, Sumida-ku, Tokyo 130-0004, Japan 26
- ¹⁰SOUSEIKAI Nishikumamoto Hospital, 1012 Koga, Tomiaimachi, Minami-ku, 27
- Kumamoto 861-4157, Japan 28
- ¹¹SOUSEIKAI Miyata Hospital, 1636 Honjo, Miyawaka, Fukuoka 823-0003, Japan 29
- ¹²SOUSEIKAI Kanenokuma Hospital, 3-24-16 Kanenokuma, Hakata-ku, Fukuoka 812-30
- 31 0863, Japan
- ¹³SOUSEIKAI Shinyoshizuka Hospital, 7-6-29, Yoshizuka, Hakata-ku, Fukuoka 812-32
- 33 0041, Japan

- ¹⁴SOUSEIKAI DoDo Clinic, 1-31-13, Nakaikegami, Ota-ku, Tokyo 146-0081, Japan 34
- ¹⁵SOUSEIKAI, 3-5-1 Kashiiteriha, Higashi-ku, Fukuoka 813–0017, Japan 35

Corresponding author: 37

- 38 Tatsuya Yoshihara, MD, PhD
- Fukuoka Mirai Hospital, Clinical Research Center, Kashiiteriha 3-5-1, Higashi-ku, 39
- 40 Fukuoka, Japan 813-0017
- 41 Tel: +81-92-662-3608
- 42Fax: +81-92-662-3612
- 43 E-mail: tatsuya-yoshihara@lta-med.com
- Keywords 45

44

47

COVID-19, SARS-CoV-2, seroprevalence, antibody, healthcare workers 46

Summary

Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. However, little is known about the prevalence of COVID-19 among healthcare workers in Japan. We aimed to examine the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among 2,160 healthcare workers in general hospitals and clinics in Japan. The prevalence of SARS-CoV-2 immunoglobulin G was 1.2% in August and October 2020, which is relatively higher than that in the general population in Japan. Because of the higher risk of COVID-19 infection, healthcare workers should be the top priority for further social support and vaccination against SARS-CoV-2.

Introduction

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. In Japan, the confirmed cases of COVID-19 remained low as of December 2020 compared with those in Europe or northern America. The low seroprevalence (0.03%–0.40%) of COVID-19 in the general population of Japan was reported in several studies conducted from June to September 2020 (1). However, the prevalence of COVID-19 among healthcare workers in Japan, who are at higher risk for COVID-19 infection (2), is not well characterized. Here, we aimed to determine the seroprevalence of immunoglobin (Ig)M and IgG antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among workers in general hospitals and clinics in Japan. Methods A multicenter prospective study was conducted in nine general hospitals and clinics of the SOUSEIKAI Medical Group: Fukuoka Mirai Hospital (FMH), Hakata Clinic (HC), PS Clinic (PC), Sumida Hospital (SH), Miyata Hospital (MH), Kanenokuma Hospital (KH), Shinyoshizuka Hospital (SYH), Nishikumamoto Hospital (NH), and DouDou

Clinic (DC). These hospitals/clinics are not designated to treat COVID-19 patients.

FMH Clinical Research Center, HC, NH Clinical Pharmacology Center, and SH are

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

specialized facilities for clinical trials (mainly Phase 1 clinical trials). FMH, PC, MH, KH, and SYH are located in Fukuoka prefecture; NH is located in Kumamoto prefecture; and DC and SH are located in Tokyo. This study was approved by the SOUSEIKAI Hakata Clinic Institutional Review Board (approval number: N-105) and registered in the UMIN Clinical Trial Registry (registration number: UMIN000041262). The people working in the hospitals/clinics of the SOUSEIKAI Medical Group were invited to participate in the study. All participants provided a written informed consent. In each survey, a questionnaire was used to obtain the following data: job title, presence of suspected COVID-19 symptoms since February 2020, and history of COVID-19 diagnosis. The participants' occupations were divided into eight categories: nurses (including nurse assistants), physicians, technicians (laboratory technicians, radiology technicians, pharmacists, clinical engineers, dental hygienists, physical therapists, occupational therapists, speech therapists, and acupuncturists), nursing care staff, office workers, receptionists, employees in clinical research units, and others (drivers, security personnel, nursery school teachers, shop workers, sanitary workers, nutritionists, and food service staff). SARS-CoV-2-specific IgM and IgG antibodies in the venous blood were

assessed using an immunochromatographic assay kit (2019-nCoV Ab Test [Colloidal

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

Gold], INNOVITA Biological Technology Co., Ltd., Tangshan, China) following the manufacturer's instructions. Blood samples were collected in August and/or October 2020. Using descriptive statistics, the difference in seropositive rates across background characteristics was assessed using a chi-square test. Two-tailed P values of <0.05 were considered significant. Statistical analyses were performed using JMP Pro 15 (SAS Institute Inc. Japan, Tokyo, Japan). Results A total of 2,160 SOUSEIKAI workers, aged 20–83 years (mean = 41.9, standard deviation =12.7; women: 1,547 [71.6%]), underwent at least one antibody test in August and/or October. IgM and/or IgG SARS-CoV-2 antibodies were detected in 33 (1.5%) and 27 (1.3%) participants in August and October, respectively (Table 1). IgG antibodies against SARS-CoV-2 were detected in 25 (1.2%) and 24 (1.2%) participants in August and October, respectively. After excluding one facility, where nosocomial infections occurred in April 2020, 13 participants (0.8%) demonstrated IgG positivity in August and October (Table 1). Of the eight participants who showed IgM positivity in August, none reported IgG positivity in October. Among the participants who showed IgG positivity in August, 95.5% (21/22) demonstrated IgG positivity in October.

The prevalence of IgG antibodies was higher among the 20–29-year and 60–69-year age groups compared with other age groups, whereas no significant difference was observed between women and men (Table 2). The prevalence of IgG antibodies was relatively, but not significantly, higher among nurses, nursing care staff, and receptionists (Table 2). Among the 28 participants who had at least one IgG-positive test result, 17 (60.7%) had suspected symptoms of COVID-19 since February 2020. Among the 14 participants diagnosed with COVID-19 prior to the antibody tests, 10 (71.4%) tested positive for IgG antibodies.

Discussion

The prevalence of SARS-CoV-2 antibodies varies among countries and cities. Europe and northern America have high prevalence of SARS-CoV-2 antibodies, whereas

Eastern Asia has a relatively low prevalence (3). In Japan, several studies conducted from June to September 2020 reported low seroprevalence of SARS-CoV-2 antibodies

(0.03%–0.40%) in the general population (1). In this study, the seroprevalence of SAR-CoV-2 IgG antibodies among healthcare workers was 1.2% in August and October

2020. It has been reported that the prevalence of SARS-CoV-2 antibodies in healthcare workers was higher than that in the general population (2,4). Our study also

demonstrated that the prevalence of SARS-CoV-2 antibodies was relatively higher in healthcare workers than in the general population in Japan.

The 20–29-year and 60–69-year age groups had high prevalence of SARS-CoV-2 IgG antibodies. Among the five participants in the 60–69-year age group who tested positive for IgG antibodies, four worked in the facility where nosocomial infection occurred in April 2020; therefore, the high prevalence among the 60–69-year age group was possibly due to nosocomial infection. The routes of infection in the 20–29-year age group have not been fully elucidated. However, the high occupational and daily activities and the demographic characteristics of asymptomatic carriers in the young age group were considered to be contributing factors.

The level of SARS-CoV-2 antibodies remain high for at least a few months after developing a COVID-19 infection (5–7). A recent study reported high levels of SARS-CoV-2 antibodies (69.0%–91.4%) 8 months after asymptomatic or mild SARS-CoV-2 infection (8). In this study, 95% (21/22) of participants who had IgG antibodies in August tested positive for IgG antibodies in October. Among the participants who had a history of acquiring COVID-19, 71.4% (10/14) showed IgG positivity up to 6 months after infection. These results support those of previous studies, which reported that IgG antibodies can be detected in the majority of patients a few months after SARS-CoV-2

infection.

One limitation of this study is that only one antibody assay kit was used. As PCR tests or antigen tests were not conducted in participants with SARS-CoV-2 IgM or IgG antibodies, it remained uncertain whether false-positive data were included. In particular, among the eight participants who tested positive for IgM antibodies alone in August, none tested positive for IgG antibodies in October. We recruited individuals working at SOUSEIKAI medical group facilities for this study; of them, 91.6% (2,142 out of 2,338) in August and 90.0% (2,081 out of 2311) in October participated in this study. Thus, the effect of selection bias is limited.

In conclusion, the prevalence of SARS-CoV-2 IgG antibodies among healthcare workers in Japan was 1.2%, which was relatively higher than that in Japan's general population. Healthcare workers are at higher risk of infection; hence, they should be the top priority for further social support and SARS-CoV-2 vaccination.

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

Acknowledgement The authors would like to thank SoftBank Group Corp. for providing the immunochromatographic assay kits, the workers at the study settings for their consent to participate and support in conducting this study, Ms. Junko Manabe and Yoshie Moriji for collecting the study data, and Editage (www.editage.com) for providing English language editing assistance. **Conflict of interest** None to declare. **Funding** This study did not receive external funding. The immunochromatographic assay kits used in this study were provided by SoftBank Group Corp. **Author contributions** TYoshihara, RU, and SI conceived and designed the study. TY, KI, and SI wrote the protocol of the study. IA, RK, TT, TYonemura, KY, SN, YT, NY, and HK conducted the study in each study setting. TY, KI, MZ, and SI analyzed and interpreted the data. TY, KI,

- MZ, and EC drafted the manuscript. All authors interpreted the results of the analyses, 181
- critically reviewed and edited the manuscript, and approved the final version. 182

References 184 185 Nawa N, Kuramochi J, Sonoda S, et al. Seroprevalence of SARS-CoV-2 IgG 1. 186 187 Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study. medRxiv. 2020. 188 doi: https://doi.org/10.1101/2020.07.20.20155945. 189 190 2. Galanis P, Vraka I, Fragkou D, et al. Seroprevalence of SARS-CoV-2 antibodies 191 and associated factors in healthcare workers: a systematic review and metaanalysis. J Hosp Infect. 2020;16(108):120-134. doi: 10.1016/j.jhin.2020.11.008. 192 Rostami A, Sepidarkish M, Leeflang MMG, et al. SARS-CoV-2 seroprevalence 193 3. 194 worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 195 2020;S1198-743X(20)30651-0. doi: 10.1016/j.cmi.2020.10.020. Abo-Leyah H, Gallant S, Cassidy D, et al. Seroprevalence of SARS-COV-2 196 4. 197 Antibodies in Scottish Healthcare Workers. medRxiv. 2020. 198 doi: https://doi.org/10.1101/2020.10.02.20205641. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to 199 5. 200 SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724-34. doi: 10.1056/NEJMoa2026116. 201

202	6.	Flehmig B, Schindler M, Ruetalo N, et al. Persisting Neutralizing Activity to
203		SARS-CoV-2 over Months in Sera of COVID-19 Patients. Viruses.
204		2020;12(12):1357. doi: 10.3390/v12121357.
205	7.	Wang Y, Li J, Li H, et al. Persistence of SARS-CoV-2-specific antibodies in
206		COVID-19 patients. Int Immunopharmacol. 2021;90:107271. doi:
207		10.1016/j.intimp.2020.107271.
208	8.	Choe PG, Kim K-H, Kang CK, et al. Antibody Responses 8 Months after
209		Asymptomatic or Mild SARS-CoV-2 Infection. Emerg Infect Dis.
210		2021;27(3). doi: 10.3201/eid2703.204543.
211		

Table 1. Prevalence of SARS2-CoV2 antibodies in August or October 2020 stratified by region

		Aug	ust 2020			Octob	per 2020	
	n	Positive, n (%)			n	Positive, n (%)		
Region (prefecture)		IgM	IgG	IgM and/or IgG		IgM	IgG	IgM and/or IgG
Fukuoka	1,746	10 (0.6)	25 (1.4)	33 (1.9)	1,698	3 (0.2)	24 (1.4)	27 (1.6)
Kumamoto	321	0 (0)	0 (0)	0 (0)	308	0 (0)	0 (0)	0 (0)
Tokyo	75	0 (0)	0 (0)	0 (0)	75	0 (0)	0 (0)	0 (0)
Total	2,142	10 (0.5)	25 (1.2)	33 (1.5)	2,081	3 (0.1)	24 (1.2)	27 (1.3)
Comparison between the facili	ties where no	socomial infect	ion occurred	and in those where no	socomial infecti	on did not occur		
Nosocomial infection (-)	1,654	10 (0.6)	13 (0.8)	21 (1.3)	1,595	3 (0.2)	13 (0.8)	16 (1.0)
Nosocomial infection (+)	488	0 (0)	12 (2.5)	12 (2.5)	486	0 (0)	11 (2.3)	11 (2.3)
P value ^{a,b}		0.09	0.003	0.06		0.34	0.009	0.03

²¹³ aPearson's chi-square test

bComparison between the facilities where nosocomial infection occurred and those where nosocomial infection did not occur

Table 2. Prevalence of SARS-CoV-2 antibodies in August and/or October 2020 stratified by COVID-19 history, decade age group, sex, and job categories

Characteristics	n	IgM Positive	IgG Positive	IgM and/or IgG Positive, n (%)	
Characteristics	n	n (%)	n (%)		
Total	2,160	10 (0.5)	28 (1.3)	36 (1.7)	
COVID-19 history (-)	2,146	10 (0.5)	18 (0.8)	26 (1.2)	
COVID-19 history (+)	14	0 (0)	10 (71.4)	10 (71.4)	
Age					
20–29	411	2 (0.5)	11 (2.7)	12 (2.9)	
30–39	587	3 (0.5)	1 (0.2)	3 (0.5)	
40–49	601	3 (0.5)	7 (1.2)	10 (1.7)	
50–59	330	0 (0.0)	4 (1.2)	4 (1.2)	
60–69	174	2 (1.2)	5 (2.9)	7 (4.0)	
≥70	57	0 (0.0)	0 (0.0)	0 (0.0)	
P value ^d		0.60	0.006	0.007	
Sex					
Female	1,547	6 (0.4)	21 (1.4)	27 (1.8)	
Male	613	4 (0.7)	7 (1.1)	9 (1.5)	
P value ^d		0.41	0.69	0.65	
Job categories					
Nurse ^a	651	3 (0.5)	11 (1.7)	14 (2.2)	
Physician	97	0 (0.0)	1 (1.0)	1 (1.0)	
Technician ^b	369	2 (0.5)	3 (0.8)	4 (1.1)	
Nursing care staff	329	2 (0.6)	8 (2.4)	9 (2.7)	
Office worker	270	2 (0.7)	2 (0.7)	4 (1.5)	
Receptionist	33	0 (0.0)	1 (3.0)	1 (3.0)	
Clinical research unit worker	192	0 (0.0)	0 (0.0)	0 (0.0)	
Other ^c	219	1 (0.5)	2 (0.9)	3 (1.4)	
P value ^d		0.95	0.25	0.33	

217 ^aNurses include assistants

215

216

218 ^bLaboratory technicians, radiology technicians, pharmacists, clinical engineers, dental hygienists, 219 physical therapists, occupational therapists, speech therapists, and acupuncturists 220 ^cDrivers, security personnel, nursery school teachers, workers in shop, sanitary workers, 221 nutritionists, and food service staff 222 ^dPearson's chi-square test